Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENTS (Details) - USD ($) $ in Millions		1 Months Ended			9 Months Ended
LICENSE AGREEMENTS (Details) - USD ($) $ in Millions	Aug. 04, 2017	Feb. 28, 2023	Jan. 31, 2022	Dec. 31, 2020	Mar. 31, 2023
XOMA (US) LLC [Member] \| Xoma License Agreement [Member] \| Upon Clinical and Regulatory Milestones \| Maximum
License Agreements
Milestone closing payment			$ 35.0
XOMA (US) LLC [Member] \| Xoma License Agreement [Member] \| After Clinical and Regulatory Milestones \| Maximum
License Agreements
Milestone closing payment			185.0
XOMA (US) LLC [Member] \| Phase 2 Clinical Trial RZ358 \| Xoma License Agreement [Member]
License Agreements
Milestone closing payment			2.0
XOMA (US) LLC [Member] \| Phase 3 Clinical Trial Rz 358 \| Xoma License Agreement [Member] \| Plan
License Agreements
Milestone closing payment			$ 5.0		$ 5.0
ActiveSite Pharmaceuticals, Inc
License Agreements
Royalties percentage	2.00%
ActiveSite Pharmaceuticals, Inc \| Development And License Agreement [Member]
License Agreements
Milestone closing payment				$ 1.0
ActiveSite Pharmaceuticals, Inc \| Development And License Agreement [Member] \| Plan \| Maximum
License Agreements
Maximum Amount of Milestone Events	$ 46.5
ActiveSite Pharmaceuticals, Inc \| Phase 2 Clinical Trial RZ402 \| Development And License Agreement [Member]
License Agreements
Milestone closing payment		$ 3.0
ActiveSite Pharmaceuticals, Inc \| Phase 3 Clinical Trial RZ 402 \| Development And License Agreement [Member] \| Plan
License Agreements
Milestone closing payment	$ 5.0